ward sequencing more genes as laboratories competed to offer panels of increasing numbers of genes (from 6 to >100) at decreasing prices. Perhaps because testing costs have fallen so greatly, insurers rarely object to multigene panels as a means of diagnosing recognized syndromes (eg, HBOC) when relevant guidelines are met. However, most payers will not cover more than 1 cancer risk assessment test, creating an incentive to sequence any genes of interest concurrently rather than sequentially. In short, multigene panels have entered the clinic, 3 and there seems little chance of forcing the genie back into the bottle. Fortunately, multigene panels offer significant benefits over sequential single-gene testing. They are cheaper, faster, and more efficient for differential diagnosis. Most important, they may identify deleterious mutations that the pedigree would not suggest, particularly for families with cancer patterns that deviate from recognized syndromes. These advances come with drawbacks, however, related to the lack of a testing track record for many genes on commercially available panels. 4 Panel testing is complicated by 3 levels of uncertainty about mutations in less widely tested genes, regarding (1) the magnitude of cancer risk (penetrance), (2) the anatomical and age-specific scope of cancer risk, and (3) the clinical relevance of missense variants in genes for which the spectrum of normalcy is poorly defined. Variants of uncertain significance (VUS) increase in frequency with the number of genes sequenced, 5 Well-designed studies are crucial to determine the clinical and societal value of multigene panel testing. Studies must evaluate cancer causation associated with mutations in unfamiliar genes (eg, BRIP1, RAD51D), particularly among families not meeting traditional syndromic criteria; must elucidate mutation prevalence and penetrance, and the anatomic, pathologic, and prognostic characteristics of associated cancers; and must evaluate panel testing's impact on the uptake and outcomes of screening and prophylactic procedures. High-priority topics include the effectiveness of clinician-patient communication and the health care delivery systems required for panel testing, with consideration of access and ethics; and the costeffectiveness of a multigene panel vs sequential single-gene testing strategy. We urgently need a bioinformatics infrastructure for data sharing, rapid VUS reclassification, and active case-finding of mutation carriers' at-risk relatives: such infrastructure will be mandatory for consideration of whole-genome sequencing in routine practice. The Table presents a proposed research agenda.
The exponential growth in data volume and complexity strains existing counseling models, 6 which entail discussion of gene-specific cancer risks and evidencebased interventions for well-studied syndromes. 4 is more critical now than ever before. We recommend referral to expert clinicians for test selection, pretest and posttest counseling whenever possible. The existing workforce is insufficient, and thus we urge a societal investment in training for genomics and precision medicine, both of genetic counselors and of interested physicians in oncology and other specialties.
The growing accessibility of genomic sequencing has a dazzling potential to transform oncology and medicine. However, the imperative to do no harm mandates that we exercise careful judgment in (1) the patients we select for multigene panel testing; (2) the number and identity of genes we sequence, with custom gene selection a rational alternative to prefabricated panels; and (3) the cancer screening and prevention strategies we advise.
Practice guidelines are evolving with emerging evidence, but it is important to maintain a clear separation between routine care and research, 4 particularly for comprehensive strategies such as wholegenome sequencing. Patient care should be guided by the family cancer history when a less-studied mutation is detected, and participation in well-designed trials of testing, communication, and intervention strategies (Table) should be strongly encouraged. Opinion Viewpoint
